FOL056 (Cardiovascular complications)

Coegin Pharma’s peptide-based drug candidates have novel and promising properties as potential innovative therapies in cardiovascular disease associated with diabetes. These new concepts will be further explored by Coegin Pharma to identify a leading drug candidate by the end of 2023, with the aim of initiating preclinical work in 2024. This work will be done in close collaboration with Lund University, where we have recently established a strategic collaboration with the internationally acknowledged researchers in diabetes and diabetes complications, Professor Anna Hultgårdh and Professor Jan Nilsson, both active at Lund University.